European Regulators OK Eversense NOW Remote Monitoring App

Senseonics Holdings Inc. has been granted approval in Europe for the Eversense NOW Remote Monitoring App for the Android Operating System. The Eversense NOW iOS platform has previously been approved and is currently available in Europe.
 
“We’re pleased to offer another tool for our Eversense users in Europe, now enabling access to this important feature for all our customers,” said Tim Goodnow, Ph.D., president and CEO of Senseonics. “With the Eversense NOW app, Eversense users can enjoy the added peace of mind that comes with knowing friends and family can remotely view real-time glucose data, see trend graphs, and receive real-time glucose alerts from anywhere.”
 
The Eversense NOW Remote Monitoring app for the Android operating system is expected to be available on the Google Play Store.
 
The Eversense XL Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels in persons age 18 and older with diabetes for up to 180 days. The system is intended to complement, not replace, fingerstick blood glucose (BG) measurements for diabetes treatment decisions. The sensor insertion and removal procedures are performed by a health care provider. The Eversense XL CGM System is a prescription device.
 
Senseonics Holdings is a medical technology company developing and manufacturing glucose monitoring products. Senseonics’ CGM systems, Eversense and Eversense XL, include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every five minutes to a mobile app on the user’s smartphone.